The most effective new cancer treatments will come from optimizing the immune response against cancer cells and tumor specific antigens.
Veterinary Cancer Therapeutics, LLC was formed by a team of veterinarians with expertise in clinical practice, business development, product development, and regulatory affairs. Veterinary Cancer Therapeutics, LLC has several programs under development including:
apSTAR Veterinary Cancer Laser System: apSTAR (Autologous Patient Specific Tumor Antigen Response), is an immune activating laser procedure. In previous in vivo cancer models, apSTAR has been shown to induce long term tumor immunity and increase the rate of primary and metastatic tumor regression.
T-Cell Receptor Vaccine (TCR Vax) - We are developing a new immune modulatory therapeutic which enhances cell mediated immunity, a component of the immune system often compromized in veterinary cancer patients. The TCR Vax platform is also being developed for a variety of other disorders including canine atopy, feline stomatitis, and infectious diseases.